Author

A M Huelskamp

Observed names: A.M. HUELSKAMP, AM Huelskamp, ANNE-MARIE HUELSKAMP, Ann Marie Huelskamp, Anne Marie Huelskamp

Institution: Pfizer (United States)

Observed institutions: Johns Hopkins University, Pfizer (United States), Johns Hopkins Medicine, Johns Hopkins Hospital

OpenAlex ID: A5111995443

Predictive factors for peripheral-blood progenitor-cell collections using a single large-volume leukapheresis after cyclophosphamide and granulocyte-macrophage colony-stimulating factor mobilization.

1995 · J L Passos-Coelho, H G Braine, et al. · Journal of Clinical Oncology · 91

Phase I trial of interferon gamma to potentiate cyclosporine-induced graft-versus-host disease in women undergoing autologous bone marrow transplantation for breast cancer.

1994 · M J Kennedy, G B Vogelsang, et al. · Journal of Clinical Oncology · 77

Phase I trial of intravenous cyclosporine to induce graft-versus-host disease in women undergoing autologous bone marrow transplantation for breast cancer.

1993 · M J Kennedy, G B Vogelsang, et al. · Journal of Clinical Oncology · 66

Absence of breast cancer cells in a single-day peripheral blood progenitor cell collection after priming with cyclophosphamide and granulocyte-macrophage colony-stimulating factor

1995 · JL Passos-Coelho, AA Ross, et al. · Blood · 58

Large-Volume Leukapheresis Using Regional Citrate Anticoagulation to Collect Peripheral Blood Progenitor Cells

1995 · JOSE L. PASSOS-COELHO, HAYDEN G. BRAINE, et al. · Journal of Hematotherapy · 48

Similar breast cancer cell contamination of single-day peripheral-blood progenitor-cell collections obtained after priming with hematopoietic growth factor alone or after cyclophosphamide followed by growth factor.

1996 · J L Passos-Coelho, A A Ross, et al. · Journal of Clinical Oncology · 46

Bone marrow micrometastases in chemotherapy-responsive advanced breast cancer: effect of ex vivo purging with 4-hydroperoxycyclophosphamide.

1994 · J Passos-Coelho, A A Ross, et al. · PubMed · 44

Phase I and pharmacologic study of the alkylating agent modulator novobiocin in combination with high-dose chemotherapy for the treatment of metastatic breast cancer.

1995 · M J Kennedy, D K Armstrong, et al. · Journal of Clinical Oncology · 36

Administration of human recombinant granulocyte colony-stimulating factor (filgrastim) accelerates granulocyte recovery following high-dose chemotherapy and autologous marrow transplantation with 4-hydroperoxycyclophosphamide-purged marrow in women with metastatic breast cancer.

1993 · M J Kennedy, J Davis, et al. · PubMed · 30

Breast self-examination proficiency and training effects: women at increased risk of breast cancer.

1992 · M E Stefanek, P Wilcox, et al. · PubMed · 20

Comparative Analysis of Breast Cancer Contamination in Mobilized and Nonmobilized Hematopoietic Grafts

1996 · A.A. ROSS, T.J. LAYTON, et al. · Journal of Hematotherapy · 11

Sixteen week dose intense chemotherapy for inoperable, locally advanced breast cancer

1993 · Deborah K. Armstrong, John H. Fetting, et al. · Breast Cancer Research and Treatment · 11

A phase 1, open-label, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of PF-07799933 (ARRY-440) as a single agent and in combination therapy in participants 16 years and older with advanced solid tumors with BRAF alterations.

2023 · J. Thaddeus Thaddeus Beck, Meredith McKean, et al. · Journal of Clinical Oncology · 6

The Effect of Aging on the Utilization of Chemotherapy for Metastatic Breast Cancer: A Population-Based Study

1997 · John H. Fetting, George W. Comstock, et al. · Cancer Investigation · 5

Works count: 14

Citation count: 549

H-index: 11

I10-index: 12